News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) And DSM Biologics Announce PER.C6(R) License Agreement With AbGenomics Corporation


1/11/2007 4:11:46 PM

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- January 11, 2007 -- Sittard/Leiden, The Netherlands, 11 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with the Taiwan-based AbGenomics Corporation. AbGenomics Corporation intends to use the PER.C6® cell line for its research, development and early clinical studies of monoclonal antibodies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES